# Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma

> **NCT05923190** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Fox Chase Cancer Center** · enrollment: 60 (actual)

## Conditions studied

- Urothelial Carcinoma
- Metastatic Urothelial Carcinoma
- Locally Advanced Urothelial Carcinoma

## Interventions

- **DRUG:** Enfortumab vedotin
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05923190
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-06-14
- **Primary completion:** 2028-07-01
- **Final completion:** 2029-07-01
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05923190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05923190, "Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05923190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*